Literature DB >> 4552811

Hydroxyurea therapy in chronic myelogenous leukemia.

B J Kennedy.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4552811     DOI: 10.1002/1097-0142(197204)29:4<1052::aid-cncr2820290454>3.0.co;2-7

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  12 in total

1.  Implications and problems in analysing cytotoxic activity of hydroxyurea in combination with a potential inhibitor of ribonucleotide reductase.

Authors:  G Nocentini; A Barzi; P Franchetti
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 2.  An overview of bone marrow transplantation for chronic myeloid leukemia.

Authors:  M J Barnett; A C Eaves; G L Phillips
Journal:  CMAJ       Date:  1990-08-01       Impact factor: 8.262

Review 3.  Pharmacokinetics and pharmacodynamics of hydroxyurea.

Authors:  P R Gwilt; W G Tracewell
Journal:  Clin Pharmacokinet       Date:  1998-05       Impact factor: 6.447

4.  Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha.

Authors:  R Hehlmann; B Anger; D Messerer; R Zankovich; L Bergmann; H J Kolb; P Meyer; U Essers; U Queisser; H Vaupel
Journal:  Blut       Date:  1988-02

5.  Phase 1 study of high-dose hydroxyurea in lung cancer.

Authors:  D Veale; B M Cantwell; N Kerr; A Upfold; A L Harris
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

6.  2-Aminopurine overrides multiple cell cycle checkpoints in BHK cells.

Authors:  P R Andreassen; R L Margolis
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

Review 7.  Adverse haematological complications of anticancer drugs. Clinical presentation, management and avoidance.

Authors:  D C Bodensteiner; G C Doolittle
Journal:  Drug Saf       Date:  1993-03       Impact factor: 5.606

Review 8.  Hydroxyurea therapy for sickle cell anemia.

Authors:  Patrick T McGann; Russell E Ware
Journal:  Expert Opin Drug Saf       Date:  2015-09-14       Impact factor: 4.250

9.  A phase I trial of high-dose continuous-infusion hydroxyurea.

Authors:  D C Smith; W P Vaughan; P R Gwilt; D L Trump
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 10.  Hydroxycarbamine: from an Old Drug Used in Malignant Hemopathies to a Current Standard in Sickle Cell Disease.

Authors:  Giovanna Cannas; Solène Poutrel; Xavier Thomas
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-02-15       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.